ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,851.70
-0.15%
S&P ASX All Technology
3,077.90
0.70%
Brent Oil
82.725
-0.96%
US Dollar vs AUD
1.49887
0.00%
Bitcoin
70,722.91
-1.02%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Sanofi (SAN)

  7. Sanofi (SAN) News

SAN

Sanofi (SAN)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:EU:SAN
DateTimeSourceHeadlineSymbolCompany
21/05/202415:30GlobeNewswire Inc.Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IAEU:SANSanofi
21/05/202415:30GlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
21/05/202415:30GlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
21/05/202406:54GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - April 2024EU:SANSanofi
21/05/202406:54GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024EU:SANSanofi
21/05/202404:15GlobeNewswire Inc.Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCOEU:SANSanofi
21/05/202404:15GlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
21/05/202404:15GlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
13/05/202415:00GlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyEU:SANSanofi
13/05/202415:00GlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireEU:SANSanofi
13/05/202415:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)EU:SANSanofi
10/05/202416:00GlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
10/05/202416:00GlobeNewswire Inc.Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccinesEU:SANSanofi
10/05/202416:00GlobeNewswire Inc.Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19EU:SANSanofi
02/05/202415:00GlobeNewswire Inc.Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsEU:SANSanofi
02/05/202415:00GlobeNewswire Inc.Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizationsEU:SANSanofi
01/05/202402:00GlobeNewswire Inc.Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024EU:SANSanofi
01/05/202402:00GlobeNewswire Inc.Press Release: Annual General Meeting of April 30, 2024EU:SANSanofi
01/05/202402:00GlobeNewswire Inc.Press Release: Annual General Meeting of April 30, 2024EU:SANSanofi
25/04/202415:30GlobeNewswire Inc.Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidanceEU:SANSanofi
25/04/202415:30GlobeNewswire Inc.Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancementsEU:SANSanofi
23/04/202415:00GlobeNewswire Inc.Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaEU:SANSanofi
23/04/202415:00GlobeNewswire Inc.Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopeniaEU:SANSanofi
23/04/202415:00GlobeNewswire Inc.Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaireEU:SANSanofi
17/04/202415:00GlobeNewswire Inc.Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisEU:SANSanofi
17/04/202415:00GlobeNewswire Inc.Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaquesEU:SANSanofi
17/04/202415:00GlobeNewswire Inc.Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisEU:SANSanofi
13/04/202404:05GlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2024EU:SANSanofi
13/04/202404:05GlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - March 2024EU:SANSanofi
09/04/202402:00GlobeNewswire Inc.Sanofi - AGM 30.04.2024 - Availability of Preparatory documentsEU:SANSanofi
 Showing the most relevant articles for your search:EU:SAN

Your Recent History

ASX
XJO
S&P ASX 200
FX
AUDUSD
AUD vs US Dollar
FX
AUDJPY
AUD vs Yen
NYSE
VZ
Verizon Communications
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
ASX
CBA
Commonwealth Bank Of Aus...
NASDAQ
TSLA
Tesla
ASX
WBC
Westpac Banking
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
SILVER
SILVER
FX
EURAUD
Euro vs AUD
FTSE
UKX
FTSE 100
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved